Testing shorter treatment options for isoniazid-monoresistant tuberculosis.
Official title: A Phase 2C Randomized, Controlled, Open-Label Trial of Novel Shortened Regimens for the Treatment of Isoniazid-Monoresistant TB (IMR-TB)
Funded at University of California, San Francisco · NIH-10764464 · Data updated 2026-11-12
This study is looking at new, shorter treatment options for people with isoniazid-monoresistant tuberculosis (IMR-TB) to see if a 4-month treatment works better and is easier to handle than the usual 6-month treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $256,504 |
| NIH project number | 1R34AI179568-01 |
| Project ID | NIH-10764464 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with isoniazid-monoresistant tuberculosis.
✕Less likely to help
Patients with drug-susceptible tuberculosis or those who do not have isoniazid-monoresistant tuberculosis may not benefit from this research.
What this research studies
This research investigates new, shorter treatment regimens for patients with isoniazid-monoresistant tuberculosis (IMR-TB), a condition affecting over a million people each year. The study will compare two novel 4-month treatment options against the current standard 6-month regimen to see which is more effective and has fewer side effects. Participants will be monitored for how quickly their sputum cultures clear and for any serious adverse events. The goal is to improve treatment outcomes and reduce the burden of IMR-TB.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatment options for patients with IMR-TB.
How similar studies have gone: Previous research has shown success in shortening treatment durations for other forms of tuberculosis, suggesting potential for similar advancements in IMR-TB.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Velasquez, Gustavo Eduardo — University of California, San Francisco
- Study coordinator: Velasquez, Gustavo Eduardo
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.